[1] Liang X,Wu Q,Luan S,et al. A Comprehensive Review of Topoisomerase Inhibitors as Anticancer Agents in the Past Decade[J]. Eur J Med Chem,2019,171:129-168. [2] Mohammed H H H,Abuo-Rahma G E A A,Abbas S H,et al. Current Trends and Future Directions of Fluoroquinolones[J]. Curr Med Chem,2019,26(17):3132-3149. [3] Musiol R. An Overview of Quinoline as a Privileged Scaffold in Cancer Drug Discovery[J]. Expert Opin Drug Discov,2017,12(6):583-597. [4] Suaifan G A R Y,Mohammed A A M. Fluoroquinolones Structural and Medicinal Developments (2013-2018): Where are We Now?[J]. Bioorg Med Chem,2019,27(14):3005-3060. [5] You Q D,Li Z Y,Huang C H,et al. Discovery of a Novel Series of Quinolone and Naphthyridine Derivatives as Potential Topoisomerase I Inhibitors by Scaffold Modification[J]. J Med Chem,2009,52(18):5649-5661. [6] Ge R L,Zhao Q,Xie Z L,et al. Synthesis and Biological Evaluation of 6-Fluoro-3-phenyl-7-piperazinyl Quinolone Derivatives as Potential Topoisomerase I Inhibitors[J]. Eur J Med Chem,2016,122:465-474. [7] XIE Yusuo,GAO Liuzhou,YAN Qiang,et al. Synthesis and Antitumor Activity of Fluoroquinolon-3-yl-s-Triazole Sulfide-ketone Thiosemicarbazone Derivatives of Ofloxacin[J]. Chinese J Appl Chem,2016,33(1):25-31(in Chinese). 谢玉锁,高柳州,闫强,等. 氟喹诺酮C-3均三唑硫醚酮缩氨基硫脲衍生物的合成及抗肿瘤活性[J]. 应用化学,2016,33(1):25-31. [8] LI Yuanyuan,ZHANG Chengxian,HUANG Wenlong,et al. Synthesis and Antitumor Activities of C-3 Thiazolotriazole Unsaturated Ketone Derivatives of Levofloxacoin[J]. Chinese J Appl Chem,2019,36(6):671-676(in Chinese). 李元元,张呈霞,黄文龙,等. 左氧氟沙星的噻唑并均三唑衍生物的合成及抗肿瘤活性[J]. 应用化学,2019,36(6):671-676. [9] ZHANG Huili,LI Ke,HUANG Wenlong,et al. Synthesis and Antitumor Activity of N-Arylidene-Rhodanine Levofloxacin Amides[J]. Chinese J Appl Chem,2019,36(8):897-903(in Chinese). 张会丽,李珂,黄文龙,等. N-(5-芳苄叉基饶丹宁)左氧氟沙星酰胺的合成及抗肿瘤活性[J]. 应用化学,2019,36(8):897-903. [10] Zhuang C L,Zhang W,Sheng C Q,et al. Chalcone:A Privileged Structure in Medicinal Chemistry[J]. Chem Rev,2017,117(12):7762-7810. |